KR20160141841A - Ｓ１ｐ 조절제 즉시 방출 투여 요법 - Google Patents

Ｓ１ｐ 조절제 즉시 방출 투여 요법 Download PDF

Info

Publication number
KR20160141841A
KR20160141841A KR1020167031062A KR20167031062A KR20160141841A KR 20160141841 A KR20160141841 A KR 20160141841A KR 1020167031062 A KR1020167031062 A KR 1020167031062A KR 20167031062 A KR20167031062 A KR 20167031062A KR 20160141841 A KR20160141841 A KR 20160141841A
Authority
KR
South Korea
Prior art keywords
day
mode
patient
dosage form
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020167031062A
Other languages
English (en)
Korean (ko)
Inventor
에릭 레강네욱스
에릭 발스트롬
필리페 미하엘 르네 보우일로트
에머릭 레이나우드
프랑크 달케
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52988364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20160141841(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Priority to KR1020227039781A priority Critical patent/KR20220156981A/ko
Publication of KR20160141841A publication Critical patent/KR20160141841A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020167031062A 2014-04-10 2015-04-08 Ｓ１ｐ 조절제 즉시 방출 투여 요법 Ceased KR20160141841A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227039781A KR20220156981A (ko) 2014-04-10 2015-04-08 Ｓ１ｐ 조절제 즉시 방출 투여 요법

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461977816P 2014-04-10 2014-04-10
US61/977,816 2014-04-10
PCT/IB2015/052550 WO2015155709A1 (en) 2014-04-10 2015-04-08 S1p modulator immediate release dosage regimen

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227039781A Division KR20220156981A (ko) 2014-04-10 2015-04-08 Ｓ１ｐ 조절제 즉시 방출 투여 요법

Publications (1)

Publication Number Publication Date
KR20160141841A true KR20160141841A (ko) 2016-12-09

Family

ID=52988364

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020167031062A Ceased KR20160141841A (ko) 2014-04-10 2015-04-08 Ｓ１ｐ 조절제 즉시 방출 투여 요법
KR1020227039781A Ceased KR20220156981A (ko) 2014-04-10 2015-04-08 Ｓ１ｐ 조절제 즉시 방출 투여 요법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020227039781A Ceased KR20220156981A (ko) 2014-04-10 2015-04-08 Ｓ１ｐ 조절제 즉시 방출 투여 요법

Country Status (16)

Country Link
US (4) US20170027907A1 (cg-RX-API-DMAC7.html)
EP (3) EP3129020A1 (cg-RX-API-DMAC7.html)
JP (1) JP6674903B2 (cg-RX-API-DMAC7.html)
KR (2) KR20160141841A (cg-RX-API-DMAC7.html)
CN (2) CN116650467A (cg-RX-API-DMAC7.html)
AU (2) AU2015246036A1 (cg-RX-API-DMAC7.html)
CA (1) CA2943598C (cg-RX-API-DMAC7.html)
CL (1) CL2016002562A1 (cg-RX-API-DMAC7.html)
IL (2) IL305337A (cg-RX-API-DMAC7.html)
MX (1) MX2016013245A (cg-RX-API-DMAC7.html)
PH (1) PH12016501965A1 (cg-RX-API-DMAC7.html)
RU (2) RU2715734C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201607894RA (cg-RX-API-DMAC7.html)
TW (1) TW201622721A (cg-RX-API-DMAC7.html)
WO (1) WO2015155709A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201606519B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (cg-RX-API-DMAC7.html) 2014-01-24 2018-02-24
SG11201607894RA (en) * 2014-04-10 2016-10-28 Novartis Ag S1p modulator immediate release dosage regimen
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
EP3687531A1 (en) * 2017-09-29 2020-08-05 Novartis AG Dosing regimen of siponimod
CN111107845A (zh) * 2017-09-29 2020-05-05 诺华股份有限公司 西尼莫德的给药方案
ES3011730T3 (en) * 2018-03-01 2025-04-08 Astrazeneca Ab Pharmaceutical compositions comprising (2s)-{(1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide
EP3823627A4 (en) 2018-07-17 2022-04-20 Insmed Incorporated CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR THE TREATMENT OF LUPUS ENEHROPATHY
CN109908095A (zh) * 2019-04-08 2019-06-21 肇庆学院 一种西尼莫德片剂及制备方法
WO2021084068A1 (en) 2019-10-31 2021-05-06 Idorsia Pharmaceuticals Ltd Combination of a cxcr7 antagonist with an s1p1 receptor modulator
WO2021158838A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Dosage regimen of an s1p receptor modulator
WO2024148308A1 (en) 2023-01-06 2024-07-11 Insmed Incorporated Novel, reversible dpp1 inhibitors and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2379497T1 (sl) * 2008-12-18 2013-12-31 Novartis Ag Hemifumaratna sol 1-(4-(1-(4-ciklohaksil-3-trifluorometil-benziloksiimino)-etil)-2-etil- benzil)azetidin-3-karboksilne kisline
HUE026869T2 (en) * 2008-12-22 2016-08-29 Novartis Ag Dosage regimen for fingolimod for the treatment of multiple sclerosis
NZ593427A (en) * 2008-12-22 2013-11-29 Novartis Ag Dosage regimen of an s1p receptor agonist
CN103933570A (zh) * 2009-09-29 2014-07-23 诺华股份有限公司 S1p受体调节剂的给药方案
JP6111202B2 (ja) * 2011-01-07 2017-04-05 ノバルティス アーゲー 免疫抑制製剤
WO2012095853A1 (en) * 2011-01-10 2012-07-19 Novartis Pharma Ag Modified release formulations comprising sip receptor modulators
SG10201602279PA (en) * 2011-10-21 2016-04-28 Novartis Ag Dosage regimen for an s1p receptor modulator or agonist
SG11201607894RA (en) * 2014-04-10 2016-10-28 Novartis Ag S1p modulator immediate release dosage regimen

Also Published As

Publication number Publication date
ZA201606519B (en) 2017-11-29
IL247986A0 (en) 2016-11-30
EP3129020A1 (en) 2017-02-15
CL2016002562A1 (es) 2017-07-28
AU2020203107A1 (en) 2020-05-28
RU2016143979A (ru) 2018-05-14
US20170027907A1 (en) 2017-02-02
IL305337A (en) 2023-10-01
RU2020107732A (ru) 2020-03-30
PH12016501965A1 (en) 2017-01-09
US20190054065A1 (en) 2019-02-21
RU2715734C2 (ru) 2020-03-03
RU2016143979A3 (cg-RX-API-DMAC7.html) 2018-11-12
KR20220156981A (ko) 2022-11-28
JP2017510607A (ja) 2017-04-13
WO2015155709A1 (en) 2015-10-15
EP3831378A1 (en) 2021-06-09
US20220016076A1 (en) 2022-01-20
CA2943598A1 (en) 2015-10-15
CN116650467A (zh) 2023-08-29
SG11201607894RA (en) 2016-10-28
CA2943598C (en) 2023-03-07
AU2015246036A1 (en) 2016-10-13
MX2016013245A (es) 2017-01-16
JP6674903B2 (ja) 2020-04-01
TW201622721A (zh) 2016-07-01
AU2020203107B2 (en) 2021-10-21
US20250041266A1 (en) 2025-02-06
EP4074312A1 (en) 2022-10-19
CN106456552A (zh) 2017-02-22

Similar Documents

Publication Publication Date Title
US20250041266A1 (en) S1p modulator immediate release dosage regimen
TWI632909B (zh) 治療阿滋海默症之方法以及其醫藥組成物
AU2018329202B2 (en) Methods for making and using endoxifen
JP2017538706A (ja) 選択的ｓ１ｐ１レセプターアゴニストの投与法
JP2010514696A (ja) 心血管症状の低減
US11944602B2 (en) Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
US7713984B2 (en) Pharmaceutical uses
AU2018343239A1 (en) Dosing regimen of siponimod
HK40081576A (en) Siponimod immediate release dosage regimen for treating autoimmune diseases
HK40053433A (en) Siponimod immediate release dosage regimen for treating autoimmune diseases
JP2008255064A (ja) 睡眠障害予防治療剤
CA2973540C (en) Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
TW202527911A (zh) 用於治療猝睡症的化合物
Taylor et al. Efficacy and tolerability of amlodipine in the general practice treatment of essential hypertension in an Asian multinational population
JPH08157368A (ja) 脳浮腫治療剤

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20161107

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200407

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210729

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220221

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20210729

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20220221

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20210929

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20200407

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20220614

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20220523

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20220221

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20210929

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20210729

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20200407

X601 Decision of rejection after re-examination
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20221114